In what can be regarded as a huge breakthrough in the fight against the highly contagious coronavirus infection, Biocon Limited has received approval from the Drugs Controller General of India (DCGI) for the use of an extracorporeal blood purification device in treatment for the virus. CytoSorb® is an in-licensed unique device that reduces cytokine storm in critically ill patients, and was introduced by Biocon in India in 2013.
As a science-led organisation, #Biocon’s endeavour is to provide innovative solutions to patients to address their unmet needs." @kiranshaw as #BioconBiologics receives DCGI Approval for emergency use of CytoSorb® to treat critical #COVID19 patients. 👉 https://t.co/DjPHHAWIXO pic.twitter.com/VcHFAqWcHC
— Biocon (@Bioconlimited) May 27, 2020
In a press release, the executive chairperson of Biocon, Kiran Mazumdar-Shaw, noted that,
DCGI approval for emergency use of CytoSorb for critical COVID-19 patients is an important example of how industry and regulators are working in tandem to urgently provide physicians and patients with new treatment options in the fight against COVID-19
Mazumdar-Shaw further added, that “with more than 80,000* documented active coronavirus infections and over 4,000* deaths, India needs new therapies to reduce the severity of this disease.”
We hope with this news, the fight against coronavirus encounters a progressive standpoint.